Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery

Qian Zhan,1 Baiyong Shen,1 Xiaxing Deng,1 Hao Chen,1 Jiabin Jin,1 Xing Zhang,2 Chenghong Peng,1 Hongwei Li1 1Department of General Surgery, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; 2Department of Surgery, University of Chicago...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhan Q, Shen B, Deng X, Chen H, Jin J, Zhang X, Peng C, Li H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/e389e36ef44745c0af6240f6dfd93dbe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e389e36ef44745c0af6240f6dfd93dbe
record_format	dspace
spelling	oai:doaj.org-article:e389e36ef44745c0af6240f6dfd93dbe2021-12-02T01:33:02ZDrug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery1176-91141178-2013https://doaj.org/article/e389e36ef44745c0af6240f6dfd93dbe2013-07-01T00:00:00Zhttp://www.dovepress.com/drug-eluting-scaffold-to-deliver-chemotherapeutic-medication-for-manag-a13633https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Qian Zhan,1 Baiyong Shen,1 Xiaxing Deng,1 Hao Chen,1 Jiabin Jin,1 Xing Zhang,2 Chenghong Peng,1 Hongwei Li1 1Department of General Surgery, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; 2Department of Surgery, University of Chicago, Chicago, IL, USA Abstract: Traditional post-surgical chemotherapy for pancreatic cancer is notorious for its devastating side effects due to the high dosage required. On the other hand, legitimate concerns have been raised about nanoparticle-mediated drug delivery because of its potential cytotoxicity. Therefore, we explored the local delivery of a reduced dosage of FOLFIRINOX, a four-drug regimen comprising oxaliplatin, leucovorin, irinotecan, and fluorouracil, for pancreatic cancer using a biocompatible drug-eluting scaffold as a novel chemotherapy strategy after palliative surgery. In vitro assays showed that FOLFIRINOX in the scaffold caused massive apoptosis and thereby a decrease in the viability of pancreatic cancer cells, confirming the chemotherapeutic capability of the drug-eluting scaffold. In vivo studies in an orthotopic murine xenograft model demonstrated that the FOLFIRINOX in the scaffold had antitumorigenic and antimetastatic effects comparable with those achieved by intraperitoneal injection, despite the dose released by the scaffold being roughly two thirds lower. A mechanistic study attributed our results to the excellent ability of the FOLFIRINOX in the scaffold to destroy the CD133+CXCR4+ cell population responsible for pancreatic tumorigenesis and metastasis. This clinically oriented study gives rise to a promising alternative strategy for postsurgical management of pancreatic cancer, featuring a local chemotherapeutic effect with considerable attenuation of side effects. Keywords: electrospun scaffold, FOLFIRINOX, pancreatic cancer, drug-eluting scaffoldZhan QShen BDeng XChen HJin JZhang XPeng CLi HDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss default, Pp 2465-2472 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Zhan Q Shen B Deng X Chen H Jin J Zhang X Peng C Li H Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery
description	Qian Zhan,1 Baiyong Shen,1 Xiaxing Deng,1 Hao Chen,1 Jiabin Jin,1 Xing Zhang,2 Chenghong Peng,1 Hongwei Li1 1Department of General Surgery, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China; 2Department of Surgery, University of Chicago, Chicago, IL, USA Abstract: Traditional post-surgical chemotherapy for pancreatic cancer is notorious for its devastating side effects due to the high dosage required. On the other hand, legitimate concerns have been raised about nanoparticle-mediated drug delivery because of its potential cytotoxicity. Therefore, we explored the local delivery of a reduced dosage of FOLFIRINOX, a four-drug regimen comprising oxaliplatin, leucovorin, irinotecan, and fluorouracil, for pancreatic cancer using a biocompatible drug-eluting scaffold as a novel chemotherapy strategy after palliative surgery. In vitro assays showed that FOLFIRINOX in the scaffold caused massive apoptosis and thereby a decrease in the viability of pancreatic cancer cells, confirming the chemotherapeutic capability of the drug-eluting scaffold. In vivo studies in an orthotopic murine xenograft model demonstrated that the FOLFIRINOX in the scaffold had antitumorigenic and antimetastatic effects comparable with those achieved by intraperitoneal injection, despite the dose released by the scaffold being roughly two thirds lower. A mechanistic study attributed our results to the excellent ability of the FOLFIRINOX in the scaffold to destroy the CD133+CXCR4+ cell population responsible for pancreatic tumorigenesis and metastasis. This clinically oriented study gives rise to a promising alternative strategy for postsurgical management of pancreatic cancer, featuring a local chemotherapeutic effect with considerable attenuation of side effects. Keywords: electrospun scaffold, FOLFIRINOX, pancreatic cancer, drug-eluting scaffold
format	article
author	Zhan Q Shen B Deng X Chen H Jin J Zhang X Peng C Li H
author_facet	Zhan Q Shen B Deng X Chen H Jin J Zhang X Peng C Li H
author_sort	Zhan Q
title	Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery
title_short	Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery
title_full	Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery
title_fullStr	Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery
title_full_unstemmed	Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery
title_sort	drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/e389e36ef44745c0af6240f6dfd93dbe
work_keys_str_mv	AT zhanq drugelutingscaffoldtodeliverchemotherapeuticmedicationformanagementofpancreaticcanceraftersurgery AT shenb drugelutingscaffoldtodeliverchemotherapeuticmedicationformanagementofpancreaticcanceraftersurgery AT dengx drugelutingscaffoldtodeliverchemotherapeuticmedicationformanagementofpancreaticcanceraftersurgery AT chenh drugelutingscaffoldtodeliverchemotherapeuticmedicationformanagementofpancreaticcanceraftersurgery AT jinj drugelutingscaffoldtodeliverchemotherapeuticmedicationformanagementofpancreaticcanceraftersurgery AT zhangx drugelutingscaffoldtodeliverchemotherapeuticmedicationformanagementofpancreaticcanceraftersurgery AT pengc drugelutingscaffoldtodeliverchemotherapeuticmedicationformanagementofpancreaticcanceraftersurgery AT lih drugelutingscaffoldtodeliverchemotherapeuticmedicationformanagementofpancreaticcanceraftersurgery
_version_	1718403046246973440

Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery

Ejemplares similares